Ahmad Tarhini, MD, PhD, on High-Risk Resectable Melanoma: Neoadjuvant Therapies

Posted: Friday, June 6, 2025

Ahmad Tarhini, MD, PhD, of H. Lee Moffitt Cancer Center & Research Institute, discusses findings from the phase II ECOG-ACRIN EA6194 trial, which investigated pembrolizumab alone and in combination with the TLR9 agonist vidutolimod as neoadjuvant therapy for patients with high-risk resectable melanoma. 

---